Skip to main content

Table 4 Baseline characteristics and mortality of norepinephrine- vs. vasopressin-treated patients before and after matching in SPH2. Sensitivity analysis after exclusion of patients who had underlying NYHA IV CHF

From: Vasopressin versus norepinephrine in septic shock: a propensity score matched efficiency retrospective cohort study in the VASST coordinating center hospital

Variable Norepinephrine Vasopressin p
Baseline characteristics norepinephrine- vs. vasopressin-treated patients before matching in SPH2
 Age (years), X ± SD 61.4 ± 16.8 60.9 ± 13.9 0.574
 APACHE II, X ± SD 21.1 ± 7.2 23.9 ± 6.4 < 0.001
 Gender (% male) 66.4 62.4 0.617
 Surgical (%) 21.0 22.6 0.761
 Renal (%) 18.2 22.6 0.376
 Hepatic (%) 10.3 15.1 0.232
 Neurological (%) 36.5 32.3 0.48
 Ventilated (%) 82.7 82.8 0.985
 Any chronic disease (%) 45.3 50.5 0.401
 Norepinephrine dose (ug/min) 14.2 ± 13.6 19.2 ± 15.9 < 0.001
Baseline characteristics norepinephrine- vs. vasopressin-treated patients after matching in SPH2
 Age (years), X ± SD 61.4 ± 14.5 60.9 ± 13.9 0.812
 APACHE II, X ± SD 23.8 ± 6.5 23.9 ± 6.4 0.939
 Gender (% male) 69.9 62.4 0.278
 Surgical (%) 19.3 22.6 0.589
 Renal (%) 20.4 22.6 0.721
 Hepatic (%) 15.1 15.1 1
 Neurological (%) 43 32.3 0.13
 Ventilated (%) 88.2 82.8  
 Any chronic disease (%) 50.5 50.5 1
 Norepinephrine dose (ug/min) 16.9 ± 14.6 19.2 ± 15.9 0.242
Mortality of norepinephrine- vs. vasopressin-treated patients after matching in SPH2
 28-day mortality (%) 26.9 31.2 0.518